(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
@ $168.85
Issued: 20 Mar 2024 @ 09:35
Return: -4.57%
Previous signal: Mar 18 - 15:52
Previous signal:
Return: -0.14 %
Live Chart Being Loaded With Signals
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)...
Stats | |
---|---|
Today's Volume | 196 334 |
Average Volume | 214 879 |
Market Cap | 16.45B |
EPS | $-0.000190 ( 2024-05-09 ) |
Next earnings date | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.34 |
ATR14 | $0.293 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Oyler John | Sell | 542 | American Depositary Shares |
2024-04-09 | Oyler John | Sell | 2 734 | American Depositary Shares |
2024-04-09 | Oyler John | Sell | 7 924 | American Depositary Shares |
2024-04-10 | Oyler John | Sell | 11 514 | American Depositary Shares |
2024-04-10 | Oyler John | Sell | 12 501 | American Depositary Shares |
INSIDER POWER |
---|
-13.18 |
Last 99 transactions |
Buy: 5 032 881 | Sell: 5 995 876 |
Volume Correlation
BeiGene Ltd. Correlation
10 Most Positive Correlations | |
---|---|
NUTX | 0.918 |
BLZE | 0.886 |
GLMD | 0.869 |
XLNX | 0.856 |
ATIF | 0.846 |
CLPT | 0.837 |
STIM | 0.834 |
CABA | 0.833 |
BDSX | 0.833 |
XEL | 0.831 |
10 Most Negative Correlations | |
---|---|
BNIXU | -0.896 |
MARA | -0.884 |
SVFD | -0.872 |
WTER | -0.869 |
MTEK | -0.862 |
HOOK | -0.861 |
GSM | -0.861 |
RMRM | -0.858 |
NEXI | -0.856 |
MPAA | -0.854 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BeiGene Ltd. Correlation - Currency/Commodity
BeiGene Ltd. Financials
Annual | 2023 |
Revenue: | $2.46B |
Gross Profit: | $1.99B (81.13 %) |
EPS: | $-8.45 |
FY | 2023 |
Revenue: | $2.46B |
Gross Profit: | $1.99B (81.13 %) |
EPS: | $-8.45 |
FY | 2022 |
Revenue: | $1.42B |
Gross Profit: | $-511.06M (-36.09 %) |
EPS: | $-19.43 |
FY | 2021 |
Revenue: | $1.18B |
Gross Profit: | $-447.86M (-38.07 %) |
EPS: | $-16.93 |
Financial Reports:
No articles found.
BeiGene Ltd.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators